Commentary: Translation of laboratory findings to clinic in the treatment of status epilepticus - A mission impossible?: Letters/Commentary

Epilepsia

Volumn 50, Issue 7, 2009, Pages 1834-1835

  Pitkänen, Asla ^a   Wasterlain, Claude C ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; NEW DRUG;

ANIMAL EXPERIMENT; CLINICAL TRIAL; DRUG RESEARCH; EPILEPTIC STATE; LETTER; PRIORITY JOURNAL; SEIZURE; ANIMAL; BIOASSAY; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG DEVELOPMENT; ECONOMICS; HUMAN; PROCEDURES; STANDARDS; STATUS EPILEPTICUS; TRANSLATIONAL RESEARCH;

ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; ENDPOINT DETERMINATION; HUMANS; STATUS EPILEPTICUS; TRANSLATIONAL RESEARCH; TRANSLATIONAL MEDICAL RESEARCH;

EID: 67649989027     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2009.02084.x     Document Type: Letter

References (2)

1. Baulac M, Pitkänen A 2009) Research priorities in epilepsy for the next decade - a representative view of the European scientific community. Epilepsia 50 : 571 578.
2. Shorvon S, Baulac M, Cross H, Trinka E, Walker M 2008) TaskForce on Status Epilepticus of the ILAE Commission for European Affairs. The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on Status Epilepticus. Epilepsia 49 (7 1277 1285.